Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 6Ovarian Neoplasms 4Breast Neoplasms 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Pancreatic Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma 2Adenocarcinoma 2Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Mesothelioma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1Kidney Neoplasms 1

Interventions

Doxorubicin 3temsirolimus 1resiquimod 1poly ICLC 1nilotinib 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1envafolimab 1enasidenib 1TQ-B3525 1Sunitinib 1Nivolumab 1Methotrexate 1Metformin 1Ifosfamide 1HhAntag691 1Epirubicin 1Dacarbazine 1Cisplatin 1Chloroquine 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Chondrosarcoma × poly ICLC × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡